10-Q quarterly report · filed Nov 4, 2026

PHIBRO ANIMAL HEALTH CORP (PAHC) Q3 2026 10-Q Quarterly Report

Short answer

PHIBRO ANIMAL HEALTH CORP (PAHC) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $387M (up 6.3% year over year) with net income of $30M.

Q3 2026 key financials · XBRL

Revenue
$387M
+6.3% YoY
Net income
$30M
+11.3% YoY
Operating margin
12.8%
Gross margin
33.2%
EPS (diluted)
$0.72
+10.8% YoY

Source: XBRL data from the PHIBRO ANIMAL HEALTH CORP (PAHC) Q3 2026 10-Q on SEC EDGAR. USD.

PHIBRO ANIMAL HEALTH CORP Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $386.8M, up 6% YoY from $363.9M, driven by Mineral Nutrition and Animal Health
  • Gross margin 33.2% vs 32.9% YoY, operating margin 12.8% vs 14.1%, net margin 7.6% vs 7.3%
  • Best segment Mineral Nutrition: revenue $73.6M, up 17%; worst Vaccines: revenue $39.5M, down 2%
  • Operating cash flow $26.1M vs $9.3M; capital expenditures $18.8M; dividends $4.9M
  • Near-term liquidity expected adequate for 12 months; Brazil virginiamycin sales fell $5.2M amid regulatory restrictions and tariff risks remain

Risk Factors

  • No material changes in risk factors from the Annual Report
  • Regulatory and compliance exposure: risks disclosed in the Annual Report remain applicable
  • Operational and market exposure: business and future results remain subject to Annual Report risks
  • Financial condition exposure: Annual Report risks could materially affect financial condition

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other PHIBRO ANIMAL HEALTH CORP quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.